

**Protect Pharmaceutical Corp.**  
**Statement of financial position**  
**As at September 30, 2024 (Unaudited)**

	Notes	As at September 30, 2024 (Unaudited)	As at December 31, 2023 (Unaudited)
USD in thousand			
<b>ASSETS</b>			
<b>Current Assets</b>			
Cash and cash equivalents	4	9,622	18,216
Trade and other receivable	5	70,127	64,390
Inventories		103,102	83,117
Other investments	6	53,932	46,897
<b>Total Current Assets</b>		<b>236,783</b>	<b>212,620</b>
Containers and handling equipment		<b>108,318</b>	<b>108,318</b>
Vessels		<b>35,915</b>	<b>33,900</b>
Intangible assets		<b>4,561</b>	<b>4,216</b>
Long term investments		<b>13,976</b>	<b>7,306</b>
<b>Total Assets</b>		<b>399,553</b>	<b>366,360</b>
<b>EQUITY &amp; LIABILITIES</b>			
<b>Current Liabilities</b>			
Accounts payable and accrued expenses	7	4,659	4,182
Provision and accruals	8	15,062	20,083
Notes payable	9	3,861	3,792
Contract liabilities	10	19,056	24,079
Employee benefits		33,283	37,862
<b>Total Current Liabilities</b>		<b>75,921</b>	<b>89,998</b>
<b>Total Liabilities</b>		<b>75,921</b>	<b>89,998</b>
<b>EQUITY</b>			
Common stock (shares authorized: 100,000,000, shares outstanding: 57,451,378)		5,745	5,745
Preferred A (shares authorized: 10,000,000, shares outstanding: 1,000,000)		1,000	-
Retained Earnings		224,705	224,705
Net profit for the year		92,182	45,912
<b>Total Equity</b>		<b>323,632</b>	<b>276,362</b>
<b>Total Liabilities and Equity</b>		<b>399,553</b>	<b>366,360</b>

**Protect Pharmaceutical Corp.**  
**Statement of profit or loss**  
**For the nine month ended September 30, 2024**

	Notes	For the nine month ended September 30, 2024	For the nine month ended September 30, 2023
USD in thousand			
Revenue	11	102,530	98,658
Cost of sales		(45,997)	(45,542)
<b>Gross profit</b>		<u>56,533</u>	<u>53,116</u>
General administrative expenses		(4,828)	(9,854)
Selling and marketing expenses		(2,839)	(5,793)
Research and development expenses		(1,484)	(3,450)
<b>Operating profit</b>		<u>47,382</u>	<u>34,019</u>
<b>Other Income / (expense)</b>			
Finance cost		-	-
<b>Profit before tax</b>		<u>47,382</u>	<u>34,019</u>
Deferred tax benefit		830	1,692
Current tax expense		(1,942)	(3,963)
<b>Profit for the year</b>		<u><u>46,270</u></u>	<u><u>31,748</u></u>

**Protect Pharmaceutical Corp.**  
**Statement of Changes in Equity**  
**As at September 30, 2024 (Unaudited)**

	Common stock		Preferred Series A stock		Previous years' profit	Net profit for the year	Total
	Shares	Amount	Shares	Amount			
	USD in thousand						
<b>As at January 1, 2024 (Unaudited)</b>	57,451,378	5,745	-	-	224,705	45,912	276,362
Issued during the period			1,000,000	1,000			1,000
Profit / (loss) for the period						46,270	46,270
<b>As at September 30, 2024 (Unaudited)</b>	<b>57,451,378</b>	<b>5,745</b>	<b>1,000,000</b>	<b>1,000</b>	<b>224,705</b>	<b>92,182</b>	<b>323,632</b>

**Protect Pharmaceutical Corp.**  
**Statement of cashflows**  
**As at September 30, 2024 (Unaudited)**

	<b>2024</b>	<b>2023</b>
	USD in thousand	
<b>Cash flow from operating activities</b>		
(Loss) / profit before income tax	46,270	45,912
Adjustment for non cash charges and other items:		
Depreciation / amortization	-	-
Unrealized exchange loss / (gain)	-	-
	<u>46,270</u>	<u>45,912</u>
Changes in working capital		
(Decrease) / increase in trade and other receivable	(5,737)	(16,140)
(Decrease) / increase in inventories	(19,985)	(120)
(Decrease) / increase in other investments	(7,035)	(1,504)
(Decrease) / increase in accounts payable and accrued expenses	477	1,129
(Decrease) / increase in provisions and accruals	(5,021)	4,480
(Decrease) / increase in notes payable	69	1,136
(Decrease) / increase in contract liabilities	(5,023)	(34,068)
(Decrease) / increase in employee benefits	(4,579)	2,849
	<u>(46,834)</u>	<u>(42,238)</u>
Cash flow from operating activities	<u>(564)</u>	<u>3,674</u>
<b>Cash flow from investing activities</b>		
Additions in containers and handling equipment	-	4,000
Additions in vessels	(2,015)	3,511
Additions in intangible assets	(345)	345
Additions in long terms investments	(6,670)	5,019
Cash flow from / (used) in investing activities	<u>(9,030)</u>	<u>12,875</u>
<b>Cash flow from financing activities</b>		
Borrowings during the year	-	-
Stock issued during the year	1,000	467
Cash flow from financing activities	<u>1,000</u>	<u>467</u>
<b>Increase / (decrease) in cash and cash equivalents</b>	<u>(8,594)</u>	<u>17,016</u>
Cash and cash equivalents at beginning of the year	18,216	1,200
<b>Cash and cash equivalents at end of the year</b>	<u><u>9,622</u></u>	<u><u>18,216</u></u>

**Protect Pharmaceutical Corp.**  
**Notes to the financial statements**  
**For the nine month ended September 30, 2024**

## **1 ORGANIZATION AND OPERATIONS OF THE COMPANY**

The Company was incorporated as a family company in Istanbul in 1989, with a purpose of providing services in the field of international partial and multimodal transportation. However, the Company has turned into logistics company that offers end-to-end solutions. Sertrans has been the reliable solution partner of its national and international customers for more than 30 years with its value-added logistics services in supply chain management.

The Company offers flexible and innovative logistics services tailored to customer needs, with its experienced and expert staff, strong vehicle fleet and equipment, advanced IT technologies and R&D team, offices spread across the country and abroad, high-capacity warehouses and warehouses

## **2 BASIS OF PREPARATION**

### **2.1 Statement of compliance**

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB). Board of Directors has approved the consolidated financial statements as of 31 December 2022. General Assembly and the related regulatory bodies have the authority to modify the statutory financial statements.

### **2.2 Accounting Convention**

These financial statements have been prepared on the basis of 'historical cost convention using accrual basis of accounting except as otherwise stated in the respective accounting policies notes.

### **2.3 Critical accounting estimates and judgements**

The preparation of financial statements in conformity with the approved accounting standards require management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised if the revision affects only that period, or in the period of the revision and future periods.

The areas involving higher degree of judgment and complexity, or areas where assumptions and estimates made by the management are significant to the financial statements are as follows:

- i) Equipment - estimated useful life of equipment (note - 3.8)
- ii) Exploration and evaluation cost (note - 3.5)
- iii) Provision for doubtful debts (note - 3.4)
- iv) Provision for income tax (note - 3.1)

### **3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

#### **3.1 Income tax**

The tax expense for the year comprises of income tax, and is recognized in the statement of earnings. The income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred income tax is accounted for using the balance sheet liability method in respect of all temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred income tax liabilities are recognised for all taxable temporary differences and deferred income tax assets are recognised to the extent that it is probable that taxable profits will be available against which the deductible temporary differences and unused tax losses can be utilized. Deferred income tax is calculated at the rates that are expected to apply to the period when the differences are expected to be reversed.

#### **3.2 Trade and other payables**

Liabilities for trade and other amounts payable are carried at cost, which is the fair value of the consideration to be paid in future for goods and services received, whether or not billed to the Company.

#### **3.3 Provisions**

A provision is recognized in the financial statements when the Company has a legal or constructive obligation as a result of past events and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of obligation.

#### **3.4 Accounts Receivable**

Accounts receivable are non-interest bearing obligations due under normal course of business. The management reviews accounts receivable on a monthly basis to determine if any receivables will be potentially uncollectible. Historical bad debts and current economic trends are used in

evaluating the allowance for doubtful accounts. The Company includes any accounts receivable balances that are determined to be uncollectible in its overall allowance for doubtful accounts. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. Based on the information available, the Company believes its allowance for doubtful accounts as of period ended is adequate.

### **3.5 Contract assets and accrued cost of services**

Contract assets and accrued costs of services include accrued revenue and accrued costs from freight forwarding services, contract logistics and other related services in progress at 31 December 2022.

Contract assets are recognised when a sales transaction fulfils the criteria for revenue recognition, but no final invoice has yet been issued to the customer for the services delivered. Accrued costs of services are estimated and recognised when supplier invoices relating to recognised revenue for the reporting period have yet to be received.

### **3.6 Contingent liabilities**

A contingent liability is disclosed when the Company has a possible obligation as a result of past events, the existence of which will be confirmed only by the occurrence or non-occurrence, of one or more uncertain future events, not wholly within the control of the Company; or when the Company has a present legal or constructive obligation, that arises from past events, but it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation, or the amount of the obligation cannot be measured with sufficient reliability.

### **3.7 Financial liabilities**

Financial liabilities are recognized when the Company becomes party to the contractual provision of the instruments and the Company loses control of the contractual right that comprise the financial liability when the obligation specified in the contract is discharged, cancelled or expired. The Company classifies its financial liabilities in two categories: at fair value through profit or loss and financial liabilities measured at amortized cost. The classification depends on the purpose for which the financial liabilities were incurred. Management determines the classification of its financial liabilities at initial recognition.

#### *(a) Financial liabilities at fair value through profit or loss*

Financial liabilities at fair value through profit or loss are financial liabilities held for trading. A financial liability is classified in this category if incurred principally for the purpose of trading or payment in the short-term. Derivatives (if any) are also categorized as held for trading unless they are designated as hedges.

#### *(b) Financial liabilities measured at amortized cost*

These are non-derivative financial liabilities with fixed or determinable payments that are not quoted in an active market. These are recognized initially at fair value, net of transaction costs incurred and are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the profit and loss account.

### **3.8 Property, plant and equipment**

All equipments are stated at cost less accumulated depreciation and impairment loss. The cost of fixed assets includes its purchase price, import duties and non-refundable purchase taxes and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Depreciation on additions to property, plant and equipment is charged, using straight line method, on pro rata basis from the month in which the relevant asset is acquired or capitalized, upto the month in which the asset is disposed off. Impairment loss, if any, or its reversal, is also charged to income for the year. Where an impairment loss is recognized, the depreciation charge is adjusted in future periods to allocate the asset's revised carrying amount, less its residual value, over its estimated useful life.

Maintenance and normal repair costs are expensed out as and when incurred. Major renewals and improvements are capitalized and assets so replaced, if any are retired.

Gains and losses on disposal of fixed assets, if any, are recognized in statement of profit or loss.

### **3.9 Cash and cash equivalents**

Cash and cash equivalents include cash in hand and deposits held at call with banks. For the purpose of the statement of cash flows, cash and cash equivalents bank balances and short term highly liquid investments subject to an insignificant risk of changes in value and with maturities of less than three months.

### **3.10 Revenue recognition**

Revenue is recognised to the extent it is probable that the economic benefits will flow to the Company and the revenue can be measured reliably. Revenue is measured at the fair value of the consideration received or receivable for goods sold or services rendered, net of discounts and sales tax and is recognised when significant risks and rewards are transferred.

### **### Functional and presentation currency**

Items included in the financial statements are measured using the currency of the primary economic environment in which the Company operates. The financial statements are presented in United States Dollars (USD) which is the Company's presentation currency. All financial information presented in USD has been rounded to the nearest dollars unless otherwise stated.



### **### Foreign currency transactions**

Foreign currency transactions are translated into the functional currency using the exchange rate prevailing on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into functional currency using the exchange rate prevailing at the statement of financial position date. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates are recognized in the statement of profit or loss.

### **### Contingencies**

The assessment of the contingencies inherently involves the exercise of significant judgment as the outcome of the future events cannot be predicted with certainty. The Company, based on the availability of the latest information, estimates the value of contingent assets and liabilities, which may differ on the occurrence / non-occurrence of the uncertain future event(s).

4 **Cash**

This represent cash in hand and cash deposited in bank accounts (current) by the Company.

	USD in thousand
<b>5 Trade and other receivable</b>	
Opening balance	64,390
Net movement in asset during the period	5,737
	<b>70,127</b>
<b>6 Other investments</b>	
Opening balance	46,897
Net movement in asset during the period	7,035
	<b>53,932</b>
<b>7 Accounts payable and accrued expenses</b>	
Opening balance	4,182
Net movement in liabilities during the period	477
	<b>4,659</b>
<b>8 Provision and accruals</b>	
Opening balance	20,083
Net movement in liabilities during the period	(5,021)
	<b>15,062</b>
<b>9 Notes payable</b>	
Opening balance	3,792
Net movement in liabilities during the period	69
	<b>3,861</b>
<b>10 Contract liabilities</b>	
Opening balance	24,079
Net movement in liabilities during the period	(5,023)
	<b>19,056</b>

## 11 Revenue

Income from voyage and related services	25,238
Freight services	
- Airline	14,466
- Seaway	24,248
- International road	20,612
	59,326
Intermodal transportation / freight	17,966
	<u>102,530</u>

## 11 Share Capital

This represents ordinary share capital issued by the Company at the par value. The shares issued by the company, if any, during the period are represented in statement of changes in equity.

## 12 Contingencies and Commitments

The company has no contingency and commitment as at the end of reporting period.

## 13 Other Information

### i) Evaluation of Disclosure Controls and Procedures

Management of the Company has evaluated, with the participation of the Chief Executive Officer and Chief Financial Officer of the Company, the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) promulgated by the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer of the Company had concluded that the Company's disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q were effective.

### ii) Changes in internal control over financial reporting .

Management of the Company has also evaluated, with the participation of the Chief Executive Officer of the Company, any change in the Company's internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q and determined that there was no change in the Company's internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

Chief Executive

Director

# Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

## PROTECT PHARMACEUTICALS CORP

A Wyoming Corporation  
12465 South Fort St., Suite 240  
Draper UT 84020

347-692-8942  
www.atlantic-logistics.net  
info@atlantic-logistics.net  
SIC 4731

## Quarterly Report

For the period ending 6/30/2024 (the "Reporting Period")

### Outstanding Shares

The number of shares outstanding of our Common Stock was:

57,451,378 as of 6/30/2024

57,451,378 as of 12/31/2023

57,451,378 as of 12/31/2022

### Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

### Change in Control

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

---

<sup>1</sup> "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

Yes:  No:

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Previously Interstate Development Inc. until 01-2007.  
Previously Pro-Tect, Inc. 1/2007 – 5/2010  
Previously Protect Pharmaceuticals Corp. 2010-2018  
An erroneous name change was filed the state of Nevada in 2018 but never implemented  
Name restored to Protect Pharmaceuticals Corp.in 2020

Current State and Date of Incorporation or Registration: Wyoming  
Standing in this jurisdiction: (e.g. active, default, inactive): Active (Good Standing)

Prior Incorporation Information for the issuer and any predecessors during the past five years:  
N/A

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:  
N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

N/A

The address(es) of the issuer's principal executive office:

\_\_\_\_\_

The address(es) of the issuer's principal place of business:  
 Check if principal executive office and principal place of business are the same address:

12465 South Fort St., Suite 240  
Draper UT 84020

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No:  Yes:  If Yes, provide additional details below:

\_\_\_\_\_

\_\_\_\_\_  
(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;  
(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or  
(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

## 2) Security Information

### **Transfer Agent**

Name: ClearTrust LLC  
Phone: (813) 235-4490  
Email: [inbox@cleartrusttransfer.com](mailto:inbox@cleartrusttransfer.com)  
Address: 16540 Pointe Village Dr Suite 205, Lutz, FL 33558

### **Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	<u>PRTT</u>	
Exact title and class of securities outstanding:	<u>COMMON STOCK</u>	
CUSIP:	<u>74364W203</u>	
Par or stated value:	<u>.005</u>	
Total shares authorized:	<u>100,000,000</u>	as of date: <u>6/30/2024</u>
Total shares outstanding:	<u>57,451,378</u>	as of date: <u>6/30/2024</u>
Total number of shareholders of record:	<u>100</u>	as of date: <u>6/30/2024</u>

*All additional class(es) of publicly quoted or traded securities (if any):*

### **Other classes of authorized or outstanding equity securities:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of securities outstanding:	<u>Preferred Series "A"</u>	
CUSIP:	<u>NONE</u>	
Par or stated value:	<u>.001</u>	
Total shares authorized:	<u>10,000,000</u>	as of date: <u>6/30/2024</u>
Total shares outstanding:	<u>1,000,000</u>	as of date: <u>6/30/2024</u>
Total number of shareholders of record:	<u>1</u>	as of date: <u>6/30/2024</u>
(if applicable):	<u>          </u>	as of date: <u>          </u>

### **Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

1. For common equity, describe any dividend, voting and preemption rights.

None

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Preferred Series A Shares vote 100 votes for each share. There are no conversion rights to common shares.

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No:  Yes:  (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End: <u>Opening Balance</u> Date <u>12/31/2022</u> Common: <u>57,451,378</u> Preferred: <u>1,000,000</u>			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to.  *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.

Shares Outstanding on Date of This Report:									
Ending Balance:									
Date 6/30/2024 Common: 57,451,378									
Preferred: 1,000,000									

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2021 through December 31, 2022 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

\_\_\_\_\_

**B. Promissory and Convertible Notes**

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer’s equity securities :

No:  Yes:  (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. *You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

\_\_\_\_\_

**4) Issuer’s Business, Products and Services**

The purpose of this section is to provide a clear description of the issuer’s current operations. (Please ensure that these descriptions are updated on the Company’s Profile on [www.otcmarkets.com](http://www.otcmarkets.com)).

A. Summarize the issuer’s business operations (If the issuer does not have current operations, state “no operations”)



Providing services in the field of international road, seaway, airline freight as well as intermodal transportation freight. Combining all transportation servicing needs.

B. List any subsidiaries, parent company, or affiliated companies.

Antarax Capital Danismanlik Limited  
Bosfor Transport

C. Describe the issuers' principal products or services.

international road, seaway, airline freight as well as intermodal transportation freight.

## 5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The main operating office is located in Istanbul Turkey and the address is Ömerli Mah. Hadımköy İstanbul Cad. No: 260 34555 Arnavutköy İstanbul

## 6) All Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuers securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
<u>Ozgur Ozcan</u>	<u>President/Director</u>	<u>Ankara Turkey</u>	0	_____	_____	_____
<u>Sergii Panchinshnyi</u>	<u>Owner of more than 5%</u>	<u>Istanbul Turkey</u>	<u>1,000,000</u>	<u>Preferred Series A</u>	<u>100%</u>	_____

_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____
						_____

**7) Legal/Disciplinary History**

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

- 1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

None

- 2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

None

- 3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

None

- 4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

None

- 5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- 6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties

thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

### 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Amber Barger  
Firm: LAW OFFICES OF M. AMBER BARGER, PLLC  
Address 1: 3901 Arlington Highlands Blvd., Suite 200  
Address 2: Arlington, TX 76018  
Phone: (682) 888-1748  
Email: [abarger@mablawoffice.com](mailto:abarger@mablawoffice.com)

Name: Alexey Tarasov  
Firm: Tarasov Law Offices  
Address 1: 5211 Reading Circle  
Address 2: Rosenberg, TX 77471  
Phone: (832) 623-6250  
Email: [Alexey@tarasovlaw.com](mailto:Alexey@tarasovlaw.com)

#### Accountant or Auditor

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

#### Investor Relations

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

*All other means of Investor Communication:*

Twitter: \_\_\_\_\_  
Discord: \_\_\_\_\_  
LinkedIn: \_\_\_\_\_  
Facebook: \_\_\_\_\_  
[Other ] \_\_\_\_\_

### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Nature of Services: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

## 9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **Alexey Tarasov**  
Title: **Attorney**  
Relationship to Issuer: **Counsel**

B. The following financial statements were prepared in accordance with:

- IFRS  
 U.S. GAAP

C. The following financial statements were prepared by (name of individual)<sup>2</sup>:

Name: **Asad Arif**  
Title: **Qualified Management Accountant**  
Relationship to Issuer: **Accountant**

Describe the qualifications of the person or persons who prepared the financial statements: **Asad worked for Price Waterhouse as a Senior Accountant for more than 7 years.**

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

Important Notes:

- Financial statements must be "machine readable". Do not publish images/scans of financial statements.

---

<sup>2</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

- All financial statements for a fiscal period must be published together with the disclosure statement in one Annual or Quarterly Report.

## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Ozgur Ozcan certify that:

1. I have reviewed this Disclosure Statement for Protect Pharmaceutical Corp;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

8/20/2024 [Date]

/s/ Ozgur Ozcan [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

### *Principal Financial Officer:*

I, Ozgur Ozcan certify that:

1. I have reviewed this Disclosure Statement for Protect Pharmaceutical Corp;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

8/20/2024 [Date]

/s/ Ozgur Ozcan [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")